<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cervical cancer screening: The cytology and human papillomavirus report</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cervical cancer screening: The cytology and human papillomavirus report</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cervical cancer screening: The cytology and human papillomavirus report</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher P Crum, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warner K Huh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark H Einstein, MD, MS, FACS, FACOG</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cervical cancer screening utilizes cervical cytology (the Pap test) and/or testing for oncogenic subtypes of human papillomavirus (HPV)  (<a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">table 1</a>). Results from these tests, along with a patient's past results (if known), are used to guide further evaluation, such as repeating cervical cytology, performing colposcopy with cervical biopsies, or less commonly, performing an excisional procedure. Treatment decisions are then made based upon diagnostic results from histologic examination.</p><p>Terminology for reporting cervical cytology is standardized by the Bethesda System, which has been revised several times; the current system was developed in 2014  (<a class="graphic graphic_figure graphicRef60116" href="/z/d/graphic/60116.html" rel="external">figure 1</a>) [<a href="#rid1">1-4</a>].</p><p>This topic will discuss components of the cervical cytology and HPV report and management of select results.</p><p>Cervical cancer screening strategies and techniques, management of cytology and HPV results, and treatment of cervical intraepithelial neoplasia (CIN), are reviewed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Cervical cancer screening: (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormal cervical cancer screening results: (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a> and  <a class="medical medical_review" href="/z/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CIN: (See  <a class="medical medical_review" href="/z/d/html/3216.html" rel="external">"Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120451 utd-content-120450">(Related Pathway(s):  <a class="utd-content-120451" href="/pathway/120451?topicRef=3205&amp;source=see_link">Cervical cancer screening: Follow-up of a Pap test with an absent endocervical transformation zone</a> and  <a class="utd-content-120450" href="/pathway/120450?topicRef=3205&amp;source=see_link">Cervical cancer screening: Follow-up of a Pap test showing partially obscuring blood or inflammation</a>.)</span></p><p></p><p class="headingAnchor" id="H1838964518"><span class="h1">COMPONENTS OF THE CYTOLOGY AND HPV REPORT</span></p><p class="headingAnchor" id="H3139741381"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The cytology and HPV report consists of  (<a class="graphic graphic_table graphicRef102346" href="/z/d/graphic/102346.html" rel="external">table 2</a>) [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A description of specimen type and test requested – Cervical or vaginal sample, conventional Pap smear, liquid-based cytology, and/or HPV test. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A description of specimen adequacy. (See <a class="local">'Cervical specimen adequacy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A general categorization (optional) – Specimens are noted as "negative for intraepithelial lesion or malignancy (NILM)," "epithelial cell abnormality," or "other." Specimens designated as "epithelial cell abnormality" or "other" are then described in the following section, "Interpretation/results."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An interpretation/result – Either the specimen is NILM (although organisms or reactive changes may be present), has an epithelial cell abnormality, or may indicate increased risk (eg, endometrial cells in a woman ≥45 years of age).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A description of any ancillary testing or automated review that was performed (eg, HPV, AutoPap).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educational notes and suggestions by the pathologist (optional).</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Cervical specimen adequacy</span><span class="headingEndMark"> — </span>Evaluation of specimen adequacy is considered by experts to be the most important quality assurance component of the Bethesda system. </p><p class="headingAnchor" id="H6"><span class="h3">Satisfactory for evaluation</span><span class="headingEndMark"> — </span>Any specimen with abnormal cells (eg, atypical squamous cells of undetermined significance [ASC-US], atypical glandular cells [AGC]) is considered satisfactory [<a href="#rid3">3</a>]. Otherwise, adequate squamous cellularity is defined as a conventional Pap smear with at least 8000 to 12,000 well-visualized squamous cells or a liquid-based preparation with a minimum of 5000 well-visualized squamous cells. (See  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing", section on 'Preparation methods'</a>.)</p><p>Cellularity may be diminished in patients who have been treated with pelvic radiation, thus this information should be included in the cytology requisition. Interpretation will depend on the clinical context and ability of the laboratory to evaluate the specimen [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3443331796"><span class="h4">Quality indicators</span><span class="headingEndMark"> — </span>If the specimen is satisfactory for evaluation, quality indicators are described [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absent EC/TZ component</strong> – The endocervical cell/transformation zone (EC/TZ) is an area of squamous metaplasia that forms between the original and current squamocolumnar junction and is the area at greatest risk for neoplasia  (<a class="graphic graphic_picture graphicRef105122" href="/z/d/graphic/105122.html" rel="external">picture 1</a>) [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/z/d/html/3216.html" rel="external">"Cervical intraepithelial neoplasia: Terminology, incidence, pathogenesis, and prevention", section on 'Cervical transformation zone'</a>.)</p><p></p><p class="bulletIndent1">An adequate EC/TZ sample requires at least 10 well-preserved endocervical or squamous metaplastic cells. Approximately 10 to 20 percent of cytology specimens lack this finding, and it is more common in adolescents and postmenopausal patients (likely due to hypoestrogenism) [<a href="#rid9">9,10</a>]. </p><p></p><p class="bulletIndent1">The significance of an absent EC/TZ component is controversial [<a href="#rid5">5,9,11-14</a>]; patients followed prospectively with repeat cervical cytology do <strong>not</strong> appear to be at an increased risk of squamous cell abnormalities or cervical intraepithelial neoplasia (CIN) [<a href="#rid9">9,14-17</a>]. However, concerns have been raised about reduced detection of glandular cells and related abnormalities (ie, endocervical adenocarcinoma) in specimens that lack an EC/TZ component [<a href="#rid18">18,19</a>]. There are few data to support or refute this concern, given that glandular abnormalities are less common than squamous abnormalities [<a href="#rid14">14,20</a>].</p><p></p><p class="bulletIndent1">Increased testing for oncogenic HPV  (<a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">table 1</a>) has not clarified this issue. While the lack of an EC/TZ component does not appear to decrease the sensitivity of HPV testing [<a href="#rid10">10,21</a>], studies including patients tested with both HPV and cytology do not routinely report the rate of Pap smears without an EC/TZ component [<a href="#rid22">22</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obscuring factors (blood, inflammation)</strong> – A specimen is considered "partially obscured" when 50 to 75 percent of the epithelial cells cannot be visualized [<a href="#rid2">2</a>]; a partially obscured specimen can still be satisfactory for evaluation. By contrast, specimens in which more than 75 percent of the cells are obscured (by blood, inflammation, or an air-drying artifact) are designated unsatisfactory [<a href="#rid3">3</a>]. (See <a class="local">'Unsatisfactory for evaluation'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interfering substances (lubricants, excessive blood)</strong> – Some lubricants or excessive blood may impact the processing of liquid cytology specimens and may result in the specimen being unsatisfactory for evaluation [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing", section on 'Gel lubricants and other contaminants'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Unsatisfactory for evaluation</span><span class="headingEndMark"> — </span>Cervical cytology is considered unsatisfactory for evaluation in approximately 1 percent of samples [<a href="#rid23">23,24</a>]. Whether these patients are at higher risk for future intraepithelial lesions or cancer is controversial [<a href="#rid25">25-27</a>].</p><p>Cervical cytology tests are designated "unsatisfactory for evaluation" for one of three reasons [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Scant cellularity – Fewer than 8000 to 12,000 well-visualized squamous cells on conventional smears and 5000 well-visualized squamous cells on liquid cytology specimens. Postmenopausal patients or those who are otherwise hypoestrogenic may have an unsatisfactory cytology result due to scant cellularity related to atrophy. </p><p></p><p class="bulletIndent1">Scant cellularity may result in a false-negative HPV test [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obscuring factors – More than 75 percent of the cells are obscured.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unlabeled or otherwise unable to be processed by the laboratory (eg, vial or slide broke); these specimens are distinguished from specimens determined to be unsatisfactory after processing.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Findings</span></p><p class="headingAnchor" id="H1080642292"><span class="h3">Cervical cytology</span><span class="headingEndMark"> — </span>The specimen is reported as either "NILM," or an epithelial cell abnormality is specified. Findings that are non-neoplastic (eg, infection, inflammation, atrophy) or are related to cancers other than cervical cancer are noted as "other" [<a href="#rid2">2</a>]. The presence of endometrial cells in a woman ≥45 years of age is also noted. </p><p class="headingAnchor" id="H13"><span class="h4">Intraepithelial cell abnormalities</span><span class="headingEndMark"> — </span>Intraepithelial abnormalities are associated with oncogenic subtypes of HPV  (<a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">table 1</a>) and cervical precancer or cancer. They are classified as squamous or glandular, though the term "atypical epithelial cells" may be used for cases where a squamous versus glandular origin cannot be determined.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell abnormalities</strong> – Squamous cervical cytologic abnormalities are reported as cervical squamous intraepithelial lesions (SIL) to differentiate these lesions from anal squamous intraepithelial lesions, which use similar terminology. (See  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment"</a>.) SIL lesions are reported as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Atypical squamous cells (ASC) are categorized as either of undetermined significance (ASC-US) or cannot exclude a high-grade squamous intraepithelial lesion (ASC-H). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low-grade squamous intraepithelial lesion<strong> </strong>(LSIL).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-grade squamous intraepithelial lesion (HSIL).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Squamous cell carcinoma.</p><p></p><p>The definition and incidence of each type of lesion is presented in the following tables  (<a class="graphic graphic_table graphicRef130851" href="/z/d/graphic/130851.html" rel="external">table 3</a>) and  (<a class="graphic graphic_table graphicRef89228" href="/z/d/graphic/89228.html" rel="external">table 4</a>). They are also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a> and  <a class="medical medical_review" href="/z/d/html/3179.html" rel="external">"Invasive cervical cancer: Epidemiology, risk factors, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glandular cell abnormalities</strong> – Glandular cells usually originate from the glandular epithelium of the endocervix or endometrium and are less common than squamous cell abnormalities. Glandular lesions are reported as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>AGC</p><p class="bulletIndent2"><span class="glyph">•</span>AGC, favor neoplastic</p><p class="bulletIndent2"><span class="glyph">•</span>Endocervical adenocarcinoma in situ (AIS)</p><p class="bulletIndent2"><span class="glyph">•</span>Adenocarcinoma</p><p></p><p>These terms are also defined in the table  (<a class="graphic graphic_table graphicRef130851" href="/z/d/graphic/130851.html" rel="external">table 3</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/3229.html" rel="external">"Cervical cytology: Evaluation of atypical and malignant glandular cells"</a> and  <a class="medical medical_review" href="/z/d/html/3218.html" rel="external">"Cervical adenocarcinoma in situ"</a> and  <a class="medical medical_review" href="/z/d/html/13929.html" rel="external">"Invasive cervical adenocarcinoma"</a>.)</p><p class="headingAnchor" id="H17"><span class="h4">Benign-appearing endometrial cells</span><span class="headingEndMark"> — </span>Benign-appearing endometrial cells (BEC) are reported only in patients ≥45 years of age [<a href="#rid3">3,4</a>]. This is a change from the prior Bethesda 2001 recommendation, which set the age at ≥40 years [<a href="#rid2">2</a>]. The change in age was made to improve the effectiveness of BEC as a predictor of endometrial hyperplasia or carcinoma; most of the studies discussed below were compiled with a threshold of 40 years based on the 2001 Bethesda guidelines.</p><p>BEC are noted in up to 12 percent of Pap cervical cytology tests, more commonly in premenopausal than postmenopausal patients [<a href="#rid29">29</a>]. The prevalence is higher in liquid-based compared with conventional cytology (0.9 versus 0.3 percent) [<a href="#rid30">30</a>]. </p><p>The presence of BEC may reflect:</p><p class="bulletIndent1"><span class="glyph">●</span>Physiologic shedding – Physiologic shedding is more common in the first half of the menstrual cycle. Combined results from two large studies showed that BEC are more likely to be identified on cervical cytology tests in the first 10 to 12 days of the menstrual cycle than in the remainder of the cycle (prevalence: 21 to 24 versus 2 percent) [<a href="#rid31">31,32</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pathologic process (eg, endometrial hyperplasia or carcinoma) – Postmenopausal patients with BEC are at an increased risk for endometrial hyperplasia or carcinoma [<a href="#rid29">29,30</a>]. In a retrospective study including over 160 postmenopausal patients, patients with versus without BEC had higher rates of endometrial carcinoma and its precursors despite the presence or absence of bleeding [<a href="#rid33">33</a>]. This included patients with postmenopausal bleeding (BEC: 16.4 versus 10.9 percent) as well as without postmenopausal bleeding (7.6 versus 0 percent). </p><p></p><p class="bulletIndent1">However, the significance of BEC in premenopausal patients is less clear [<a href="#rid34">34-40</a>]. As an example, in a retrospective cohort study including 186 patients ≥40 years (median 48 years, menopausal status was not assessed) with abnormal uterine bleeding, patients with versus without BEC on cervical cytology had similar rates of atypical endometrial hyperplasia (1.6 versus 1 percent) or endometrial carcinoma (2.2 versus 2.3 percent) [<a href="#rid41">41</a>]. </p><p></p><p>A finding of BEC does <strong>not</strong> include atypical endometrial cells. </p><p class="headingAnchor" id="H18"><span class="h4">Other types of malignancy</span><span class="headingEndMark"> — </span>The presence of any other types of malignant cells is described. As an example, cervical cytology may occasionally identify malignant cells from the fallopian tube, ovary, endometrium, peritoneum, vulva, or vagina. In these cases, referral to a gynecologic oncologist is recommended.</p><p class="headingAnchor" id="H1092048349"><span class="h4">Non-neoplastic findings (infection or inflammation)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious organisms</strong> – Pap tests may detect an infectious organism; however, it is not an effective test for diagnosing a cervical or vaginal infection. When an infectious organism is identified or suggested, the patient should be notified of the result, asked if they are symptomatic, and evaluated further if appropriate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Trichomonas – Trichomonads are sometimes reported as an incidental finding on tests performed for cervical cancer screening. (See  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis", section on 'Less accurate'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Liquid-based cervical cytology is not a sensitive test for diagnosis of trichomoniasis, but treatment of patients with trichomonads noted on liquid-based cervical cytology is reasonable since specificity is high [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Conventional Pap smears do not perform as well for diagnosis of trichomoniasis [<a href="#rid43">43</a>]. Asymptomatic patients with trichomonads identified on a conventional Pap smear need confirmation with clinical testing before treatment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bacterial vaginosis (BV) – Cervical cytology is not a reliable diagnostic method for BV. A Pap that is suggestive of BV will show a shift in microbiota from predominantly lactobacilli to predominantly coccobacilli with or without clue cells [<a href="#rid44">44</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Actinomyces</em> – <em>Actinomyces</em> may be identified on cervical cytology tests, typically in patients who have an intrauterine device. Cervical cytology is not the most specific test for <em>actinomyces</em>. For patients who are found to have <em>actinomyces</em> on a Pap test, we evaluate for symptoms of pelvic inflammatory disease and perform a cervical culture for <em>actinomyces</em>. (See  <a class="medical medical_review" href="/z/d/html/5422.html" rel="external">"Intrauterine contraception: Management of side effects and complications", section on 'Actinomyces and related organisms'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Herpes simplex – Rarely, herpes simplex may produce characteristic cytopathologic changes (multinucleated giant cells) in a cervical cytology specimen. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chlamydia – Chlamydia infection <strong>cannot</strong> be reliably diagnosed by cervical cytology tests [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">"Clinical manifestations and diagnosis of <i>Chlamydia trachomatis </i>infections", section on 'Diagnosis of chlamydial infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reactive changes/inflammation</strong> – Most patients with reactive changes due to inflammation will not have an organism identified on their cervical cytology test; further sampling is not required.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parabasal cells</strong> – Parabasal cells are most likely to be seen prior to menarche or following menopause, when the epithelium is not fully glycogenated. They have no clinical significance but may be confused with dysplastic cells due to their immature appearance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperkeratosis</strong> – Hyperkeratosis or parakeratosis on an otherwise negative cervical cytology test is not a marker for clinically significant CIN and may be related to infection or trauma with inflammation, such as from diaphragm use [<a href="#rid46">46,47</a>]. We do not perform colposcopy based on this finding. We repeat the cervical cytology test in 6 to 12 months, depending upon whether the patient is at increased risk for CIN, such as immunocompromised or age less than 30. If hyperkeratosis persists, treatment with topical estrogen may resolve the finding, but no treatment is necessary. </p><p></p><p class="headingAnchor" id="H927390396"><span class="h3">HPV</span><span class="headingEndMark"> — </span>The HPV report consists of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A description of specimen type and test performed (eg, cervical sample, liquid-based specimen). There are various HPV testing systems available, and the specific test used is recorded  (<a class="graphic graphic_table graphicRef129179" href="/z/d/graphic/129179.html" rel="external">table 5</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An interpretation/result – A positive result is reported if any one or more of a set of high-risk types are detected  (<a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">table 1</a>). The types that are tested have slight variation across tests, but all test for at least the 13 most common types. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A description of HPV genotyping results, if performed – HPV genotyping refers to testing for individual HPV types, usually HPV 16 or 18, but some tests may also include HPV 45.</p><p></p><p class="headingAnchor" id="H9531307"><span class="h1">MANAGEMENT OF RESULTS</span><span class="headingEndMark"> — </span>Management of results is discussed here and an overview is shown in the algorithm. </p><p class="headingAnchor" id="H3049245643"><span class="h2">Absent EC/TZ</span><span class="headingEndMark"> — </span>Most experts agree with the American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines, which advise managing patients negative for an intraepithelial lesion or malignancy (NILM) but with an absent or insufficient endocervical cell/transformation zone (EC/TZ) component as follows  (<a class="graphic graphic_algorithm graphicRef127902" href="/z/d/graphic/127902.html" rel="external">algorithm 1</a>) [<a href="#rid48">48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients age ≥30 years are managed based on the cotested high-risk HPV test results:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HPV-positive – Options for further evaluation include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Genotyping for HPV types 16 and 18, or </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>HPV and cytology cotesting in one year</p><p></p><p class="bulletIndent2">With either option, results should be managed as appropriate. (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HPV-negative – Resume routine screening.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No HPV or HPV-unknown – Options for further evaluation include: </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>HPV testing (preferred), or </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Repeat cytology in three years (acceptable)</p><p></p><p class="bulletIndent1">In our practice, for postmenopausal patients in whom the Pap test showed an absent EC/TZ, we prescribe a six-week course of vaginal estrogen prior to performing another Pap test. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients ages 21 to 29 years may return to routine screening with no further testing. However, based on reports of an increasing number of cervical adenocarcinoma in situ and adenocarcinoma cases in this age group, repeating the Pap in 12 months is also reasonable.</p><p></p><p class="headingAnchor" id="H1370646180"><span class="h2">Unsatisfactory for evaluation</span><span class="headingEndMark"> — </span>Patients with an unsatisfactory cervical cytology result are managed based on age and high-risk HPV testing results, if available. Patients with two consecutive unsatisfactory cervical cytology specimens are managed with colposcopy [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H173076939"><span class="h3">Patients ≥25 years</span><span class="headingEndMark"> — </span>We follow the ASCCP management guidelines, which recommend the following  (<a class="graphic graphic_algorithm graphicRef127901" href="/z/d/graphic/127901.html" rel="external">algorithm 2</a>) [<a href="#rid48">48</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>HPV 16/18 positive – Colposcopy (with repeat cytology)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV-positive (unknown genotype)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colposcopy (with repeat cytology), <strong>or</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeat cytology in two to four months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV-negative, no HPV performed, or HPV-unknown – Repeat cytology in two to four months. While a negative HPV test is often adequate despite cytology cellularity being insufficient, there is a possibility, albeit small, of a false-negative HPV test [<a href="#rid28">28</a>].</p><p></p><p><span class="utd-adt-cnt utd-adt-pathwys utd-content-120449">(Related Pathway(s):  <a class="utd-content-120449" href="/pathway/120449?topicRef=3205&amp;source=see_link">Cervical cancer screening: Follow-up of a Pap test reported as "unsatisfactory"</a>.)</span></p><p>When a repeat Pap is performed, recommendations regarding when to start HPV testing vary by professional organization, with some starting HPV testing at age 25 and others starting HPV testing at age 30  (<a class="graphic graphic_table graphicRef82951" href="/z/d/graphic/82951.html" rel="external">table 6</a>).</p><p class="headingAnchor" id="H748931601"><span class="h3">Patients &lt;25 years</span><span class="headingEndMark"> — </span>HPV testing is <strong>not</strong> recommended for patients &lt;25 years; thus, management of such patients with an unsatisfactory cytology result in whom screening for HPV was inadvertently performed is unclear and practice patterns differ. In our practice, we perform the following:</p><p class="bulletIndent1"><span class="glyph">●</span>HPV 16/18 positive or HPV-positive (unknown genotype)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Colposcopy (with repeat cytology), <strong>or</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Repeat cytology in two to four months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV negative – Some contributors repeat cytology in two to four months; other contributors delay repeat cytology until one year as patients with a negative HPV result are at low risk for developing cervical cancer.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV unknown or not performed – Repeat cytology in two to four months.</p><p></p><p class="headingAnchor" id="H1231821280"><span class="h3">Special considerations</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with infection</strong> – Patients with an unsatisfactory result in whom a specific infection is identified on the Pap test report or through other testing (eg, microscopy [wet prep]) should be treated prior to repeating the Pap test. (See <a class="local">'Non-neoplastic findings (infection or inflammation)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postmenopausal patients</strong> – Postmenopausal patients with an unsatisfactory result (who have no contraindications to estrogen therapy) may be treated with a short course of vaginal estrogen (eg, at least five days or up to six to eight weeks) prior to repeating the Pap test [<a href="#rid49">49</a>]. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who have been</strong> <strong>inadvertently screened</strong> – In some cases, a Pap test has been performed even though cervical cancer screening test was not indicated. Typically, the Pap test was performed too soon after a previous test. This may happen if a clinician does not have access to previous results or does not follow guidelines. If a patient with previous normal cervical cancer screening who is not due for a Pap test has an unsatisfactory specimen, the test does not have to be repeated and the patient should continue with routine screening. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a>.)</p><p></p><p class="headingAnchor" id="H285095930"><span class="h2">Benign-appearing endometrial cells</span><span class="headingEndMark"> — </span>For patients with benign-appearing endometrial cells (BEC) on a cervical cytology specimen, evaluation for endometrial hyperplasia or carcinoma is performed for all postmenopausal patients with this finding and for premenopausal patients with risk factors (eg, prior endometrial hyperplasia, <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> use, chronic anovulation, obesity, diabetes)  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 7</a>) or symptoms (eg, abnormal uterine bleeding) of endometrial carcinoma [<a href="#rid48">48</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3249.html" rel="external">"Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">"Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5421.html" rel="external">"Approach to the patient with postmenopausal uterine bleeding"</a>.)</p><p>Patients for whom menopausal status is uncertain are evaluated as if they are postmenopausal. (See  <a class="medical medical_review" href="/z/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H596454472"><span class="h2">HPV-positive results</span><span class="headingEndMark"> — </span>A patient with a positive high-risk HPV result is at an increased risk of cervical neoplasia. These patients are managed based on the combination of HPV and cytology results, according to standard guidelines, which are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p>General considerations include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>HPV 16/18</strong> – HPV 16 or 18 positivity is the highest risk clinical scenario and is an indication for immediate referral to colposcopy and, if combined with a high-grade squamous intraepithelial lesion (HSIL), expedited treatment with an excisional procedure [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening", section on 'Expedited treatment: Immediate risk &gt;60 percent'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First positive result</strong> – This is a common finding and, if there is no prior HPV-positive testing, most likely represents a new infection. Most new infections will revert to a negative result within 6 to 12 months [<a href="#rid50">50-52</a>]. Importantly, a subsequent negative HPV test in this setting does not mean the patient has cleared the HPV virus, but rather that the virus is dormant and below the threshold of a positive test. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrent positive result</strong> – Positive HPV testing may recur after reversion to HPV-negative status [<a href="#rid53">53-55</a>]. Often, it is the same HPV type as a past infection, suggesting a "reactivation" from a latent infection, but it can also be a new infection. </p><p></p><p class="bulletIndent1">Patients are counseled that most infections detected over the years of screening are reactivations of latent infections that are acquired at or near sexual debut [<a href="#rid53">53,54</a>]. Reactivation of a latent infection could imply waning immunity, and the patient might be at increased risk of persistence. This is particularly common in immunocompromised individuals [<a href="#rid53">53,54</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent positive result</strong> – Persistent HPV infection (defined as consecutively positive HPV results at least 12 months apart [<a href="#rid56">56</a>]) is a necessary pathogenetic step for progression to clinically relevant disease. Most, if not all, patients with persistent HPV infection will be diagnosed with cervical intraepithelial neoplasia 2 or more (CIN 2+) within five to seven years, many in as few as two years [<a href="#rid57">57</a>]. </p><p></p><p class="bulletIndent1">Patients with persistent positive results, but in whom further work-up (with cytology and colposcopic biopsies) is reassuring, are evaluated with vaginal colposcopy. If vaginal colposcopy is negative, continued surveillance with cervical cytology and colposcopy is prudent as the patient remains at risk for cervical cancer. </p><p></p><p class="headingAnchor" id="H1888449722"><span class="h2">All other results</span><span class="headingEndMark"> — </span>Management of all other results obtained from cytology and HPV testing are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/128059.html" rel="external">"Cervical cancer screening: Risk assessment, evaluation, and management after screening"</a>.)</p><p class="headingAnchor" id="H2416502467"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H9531352"><span class="h2">Vaginal cytology</span><span class="headingEndMark"> — </span>If vaginal cytology is performed, the findings are reported in the same manner as cervical cytology. The sample should be labeled as a vaginal sample because pathology evaluation cannot typically differentiate between vaginal and cervical squamous cells. If endocervical columnar or benign glandular cells are present, this is mentioned in the pathology report. Benign glandular cells are seen in fewer than 2 percent of vaginal cytology specimens following hysterectomy [<a href="#rid58">58</a>]. They are presumed to be the consequence of either columnar metaplasia or reactive phenomena, and do not require further evaluation.</p><p>Indications for obtaining vaginal cytology are discussed in detail separately: </p><p class="bulletIndent1"><span class="glyph">●</span>Cervical intraepithelial neoplasia (CIN) 2,3 or cervical adenocarcinoma in situ prior to or diagnosed at the time of total hysterectomy. (See  <a class="medical medical_review" href="/z/d/html/89208.html" rel="external">"Cervical intraepithelial neoplasia: Choosing excision versus ablation, and prognosis and follow-up after treatment", section on 'Type and duration of testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior vaginal cancer. (See  <a class="medical medical_review" href="/z/d/html/3221.html" rel="external">"Vaginal cancer", section on 'Post-treatment surveillance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior cervical, vulvar, or anal cancer. (See  <a class="medical medical_review" href="/z/d/html/3227.html" rel="external">"Invasive cervical cancer: Patterns of recurrence and post-treatment surveillance", section on 'Surveillance strategies'</a> and  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'Post-treatment surveillance and assessing the local response to primary chemoradiotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In-utero exposure to diethylstilbestrol (DES). (See  <a class="medical medical_review" href="/z/d/html/5427.html" rel="external">"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals", section on 'Vaginal or cervical clear cell adenocarcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunosuppression (eg, human immunodeficiency infection, history of solid organ or hematopoietic cell transplant). (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings", section on 'Screening in higher risk patients'</a>.)</p><p></p><p>Patients who have undergone a total hysterectomy (removal of the uterus and cervix) and have no history of gynecologic neoplasia do <strong>not</strong> require continued screening. Vaginal cancer is rare in these patients (&lt;1 per 100,000 women). If screening is performed (despite guidelines against this practice), and an abnormality is found, follow-up is determined based upon severity of the cytologic findings and clinical estimation of risk of vaginal cancer [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">"Screening for cervical cancer in resource-rich settings", section on 'Prior benign hysterectomy'</a> and  <a class="medical medical_review" href="/z/d/html/3260.html" rel="external">"Colposcopy", section on 'Vaginal colposcopy'</a> and  <a class="medical medical_review" href="/z/d/html/3233.html" rel="external">"Vaginal intraepithelial neoplasia"</a>.)</p><p class="headingAnchor" id="H3083089372"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117738.html" rel="external">"Society guideline links: Cervical cancer screening, prevention, and management"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16110.html" rel="external">"Patient education: Cervical cancer screening tests (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/8412.html" rel="external">"Patient education: Cervical cancer screening (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the cytology and HPV report</strong> – Cervical cancer screening utilizes cervical cytology (the Pap test) and/or testing for human papillomavirus (HPV) subtypes that are high risk for causing cervical cancer  (<a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">table 1</a>). Results are reported in a standardized format  (<a class="graphic graphic_table graphicRef102346" href="/z/d/graphic/102346.html" rel="external">table 2</a>). (See <a class="local">'Overview'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absent EC/TZ</strong> – Patients in whom cytology is negative for an intraepithelial lesion but have no endocervical cell/transformation zone (EC/TZ) component are managed according to the algorithm  (<a class="graphic graphic_algorithm graphicRef127902" href="/z/d/graphic/127902.html" rel="external">algorithm 1</a>). (See <a class="local">'Absent EC/TZ'</a> above.):</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unsatisfactory for evaluation</strong> – Patients in whom cytology is unsatisfactory for evaluation<strong> </strong>(typically due to scant cellularity in the specimen) are managed based on age and HPV testing results, if available. (See <a class="local">'Unsatisfactory for evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients ≥25 years are managed according to the algorithm  (<a class="graphic graphic_algorithm graphicRef127901" href="/z/d/graphic/127901.html" rel="external">algorithm 2</a>). (See <a class="local">'Patients ≥25 years'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HPV testing is <strong>not </strong>recommended for patients &lt;25 years; thus, management of such patients with an unsatisfactory cytology result in whom screening for HPV was inadvertently performed is unclear and practice patterns differ. (See <a class="local">'Patients &lt;25 years'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benign-appearing endometrial cells</strong> – Benign-appearing endometrial cells (BEC) are reported only in patients ≥45 years. Evaluation for endometrial hyperplasia or carcinoma is performed for all postmenopausal patients with this finding and for select premenopausal patients (eg, risk factors  (<a class="graphic graphic_table graphicRef62089" href="/z/d/graphic/62089.html" rel="external">table 7</a>) or symptoms [ie, abnormal uterine bleeding] of endometrial carcinoma)  (<a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">table 8</a>). (See <a class="local">'Benign-appearing endometrial cells'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>HPV-positive results</strong> – Patients with a positive high-risk HPV result are at an increased risk of cervical neoplasia. (See <a class="local">'HPV-positive results'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HPV 16 or 18 positivity is the highest risk clinical scenario and is an indication for immediate referral to colposcopy and, if combined with other high-risk history (eg, high-grade squamous intraepithelial lesion [HSIL]), immediate treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A first positive result most likely represents a new infection. Most new infections will revert to a negative result within 6 to 12 months. However, a negative HPV test does not mean the patient has cleared the virus, but rather that the virus is dormant and below the threshold of a positive result.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A recurrence of HPV-positive testing after a period of negative testing is often a "reactivation" from a latent infection but may also be a new infection. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Persistent HPV infection (HPV-positive results at least 12 months apart) reflects an increased risk of development of or progression to clinically relevant disease (cervical intraepithelial neoplasia 2 or more severe [CIN 2+]). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intraepithelial cell abnormalities</strong> – Patients with squamous or glandular abnormalities on cervical cytology  (<a class="graphic graphic_table graphicRef130851" href="/z/d/graphic/130851.html" rel="external">table 3</a>) require further assessment to exclude cancer or a precancerous lesion. (See <a class="local">'Intraepithelial cell abnormalities'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaginal cytology</strong> – Following total hysterectomy, vaginal cytology is <strong>not</strong> required for most patients, particularly those with documented benign cervical findings in the hysterectomy specimen. If vaginal cytology is performed and abnormalities are found, the indications for further evaluation with vaginal colposcopy are the same as for abnormal cervical cytology findings. (See <a class="local">'Vaginal cytology'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Broder S. From the National Institutes of Health. JAMA 1992; 267:1892.</a></li><li><a class="nounderline abstract_t">Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.</a></li><li><a class="nounderline abstract_t">Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathol 2015; 123:271.</a></li><li><a class="nounderline abstract_t">Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis 2015; 19:175.</a></li><li><a class="nounderline abstract_t">Davey DD, Cox JT, Austin RM, et al. Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection. J Low Genit Tract Dis 2008; 12:71.</a></li><li><a class="nounderline abstract_t">Joste N. Overview of the cytology laboratory: specimen processing through diagnosis. Obstet Gynecol Clin North Am 2008; 35:549.</a></li><li><a class="nounderline abstract_t">Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890.</a></li><li><a class="nounderline abstract_t">Herfs M, Yamamoto Y, Laury A, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A 2012; 109:10516.</a></li><li><a class="nounderline abstract_t">Baer A, Kiviat NB, Kulasingam S, et al. Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry? Obstet Gynecol 2002; 99:1053.</a></li><li><a class="nounderline abstract_t">Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer 2008; 114:242.</a></li><li><a class="nounderline abstract_t">Vooijs PG, Elias A, van der Graaf Y, Veling S. Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. Acta Cytol 1985; 29:323.</a></li><li><a class="nounderline abstract_t">Kivlahan C, Ingram E. Papanicolaou smears without endocervical cells. Are they inadequate? Acta Cytol 1986; 30:258.</a></li><li><a class="nounderline abstract_t">Martin-Hirsch P, Lilford R, Jarvis G, Kitchener HC. Efficacy of cervical-smear collection devices: a systematic review and meta-analysis. Lancet 1999; 354:1763.</a></li><li><a class="nounderline abstract_t">Mitchell HS. Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status. Cancer 2001; 93:237.</a></li><li><a class="nounderline abstract_t">Mitchell H, Medley G. Longitudinal study of women with negative cervical smears according to endocervical status. Lancet 1991; 337:265.</a></li><li><a class="nounderline abstract_t">Bos AB, van Ballegooijen M, van den Akker-van Marle ME, et al. Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears. Am J Clin Pathol 2001; 115:851.</a></li><li><a class="nounderline abstract_t">Tacken MA, Braspenning JC, Mulder J, et al. Loss to follow-up of cervical smears without endocervical columnar cells is not disturbing. Eur J Gynaecol Oncol 2006; 27:42.</a></li><li><a class="nounderline abstract_t">van der Horst J, Siebers AG, Bulten J, et al. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med 2017; 6:416.</a></li><li><a class="nounderline abstract_t">Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol 2000; 78:97.</a></li><li><a class="nounderline abstract_t">Mitchell H, Hocking J, Saville M. Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study. Acta Cytol 2004; 48:595.</a></li><li><a class="nounderline abstract_t">Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol 2009; 115:257.</a></li><li><a class="nounderline abstract_t">Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer 2002; 95:2145.</a></li><li><a class="nounderline abstract_t">Moriarty AT, Clayton AC, Zaleski S, et al. Unsatisfactory reporting rates: 2006 practices of participants in the college of american pathologists interlaboratory comparison program in gynecologic cytology. Arch Pathol Lab Med 2009; 133:1912.</a></li><li><a class="nounderline abstract_t">Hoda RS, Loukeris K, Abdul-Karim FW. Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences. Diagn Cytopathol 2013; 41:257.</a></li><li><a class="nounderline abstract_t">Hock YL, Ramaiah S, Wall ES, et al. Outcome of women with inadequate cervical smears followed up for five years. J Clin Pathol 2003; 56:592.</a></li><li><a class="nounderline abstract_t">Ransdell JS, Davey DD, Zaleski S. Clinicopathologic correlation of the unsatisfactory Papanicolaou smear. Cancer 1997; 81:139.</a></li><li><a class="nounderline abstract_t">Adams AL, Gidley J, Roberson J, et al. Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion. Am J Clin Pathol 2005; 123:738.</a></li><li><a class="nounderline abstract_t">Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17:S1.</a></li><li><a class="nounderline abstract_t">Fadare O, Ghofrani M, Chacho MS, Parkash V. The significance of benign endometrial cells in cervicovaginal smears. Adv Anat Pathol 2005; 12:274.</a></li><li><a class="nounderline abstract_t">Canfell K, Kang YJ, Clements M, et al. Normal endometrial cells in cervical cytology: systematic review of prevalence and relation to significant endometrial pathology. J Med Screen 2008; 15:188.</a></li><li><a class="nounderline abstract_t">Vooijs GP, van der Graaf Y, Vooijs MA. The presence of endometrial cells in cervical smears in relation to the day of the menstrual cycle and the method of contraception. Acta Cytol 1987; 31:427.</a></li><li><a class="nounderline abstract_t">LIU W, BARROW MJ, SPITLER MF, KOCHIS AF. NORMAL EXFOLIATION OF ENDOMETRIAL CELLS IN PREMENOPAUSAL WOMEN. Acta Cytol 1963; 7:211.</a></li><li><a class="nounderline abstract_t">Aslan DL, Crapanzano JP, Harshan M, et al. The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers. Gynecol Oncol 2007; 107:86.</a></li><li><a class="nounderline abstract_t">Bean SM, Connolly K, Roberson J, et al. Incidence and clinical significance of morphologically benign-appearing endometrial cells in patients age 40 years or older: the impact of the 2001 Bethesda System. Cancer 2006; 108:39.</a></li><li><a class="nounderline abstract_t">Greenspan DL, Cardillo M, Davey DD, et al. Endometrial cells in cervical cytology: review of cytological features and clinical assessment. J Low Genit Tract Dis 2006; 10:111.</a></li><li><a class="nounderline abstract_t">Thrall MJ, Kjeldahl KS, Savik K, et al. Significance of benign endometrial cells in papanicolaou tests from women aged &gt;or=40 years. Cancer 2005; 105:207.</a></li><li><a class="nounderline abstract_t">Simsir A, Carter W, Elgert P, Cangiarella J. Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001. Am J Clin Pathol 2005; 123:571.</a></li><li><a class="nounderline abstract_t">Ashfaq R, Sharma S, Dulley T, et al. Clinical relevance of benign endometrial cells in postmenopausal women. Diagn Cytopathol 2001; 25:235.</a></li><li><a class="nounderline abstract_t">Chang A, Sandweiss L, Bose S. Cytologically benign endometrial cells in the papanicolaou smears of postmenopausal women. Gynecol Oncol 2001; 80:37.</a></li><li><a class="nounderline abstract_t">Beal HN, Stone J, Beckmann MJ, McAsey ME. Endometrial cells identified in cervical cytology in women &gt; or = 40 years of age: criteria for appropriate endometrial evaluation. Am J Obstet Gynecol 2007; 196:568.e1.</a></li><li><a class="nounderline abstract_t">Moatamed NA, Le LT, Levin MR, et al. In Papanicolaou smears, benign appearing endometrial cells bear no significance in predicting uterine endometrial adenocarcinomas. Diagn Cytopathol 2013; 41:335.</a></li><li><a class="nounderline abstract_t">Lara-Torre E, Pinkerton JS. Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear. Am J Obstet Gynecol 2003; 188:354.</a></li><li><a class="nounderline abstract_t">Wiese W, Patel SR, Patel SC, et al. A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis. Am J Med 2000; 108:301.</a></li><li><a class="nounderline abstract_t">Greene JF 3rd, Kuehl TJ, Allen SR. The papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy. Am J Obstet Gynecol 2000; 182:1048.</a></li><li><a class="nounderline abstract_t">Pandit AA, Klhilnani PH, Powar HS, et al. Value of Papanicolaou smear in detection of Chlamydia trachomatis infection. Diagn Cytopathol 1993; 9:164.</a></li><li><a class="nounderline abstract_t">Zahn CM, Askew AW, Hall KL, Barth WH Jr. The significance of hyperkeratosis/parakeratosis on otherwise normal Papanicolaou smears. Am J Obstet Gynecol 2002; 187:997.</a></li><li><a class="nounderline abstract_t">Cecchini S, Iossa A, Ciatto S, et al. Colposcopic survey of Papanicolaou test-negative cases with hyperkeratosis or parakeratosis. Obstet Gynecol 1990; 76:857.</a></li><li><a class="nounderline abstract_t">Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis 2020; 24:102.</a></li><li><a class="nounderline abstract_t">Bateson DJ, Weisberg E. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Menopause 2009; 16:765.</a></li><li><a class="nounderline abstract_t">Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995.</a></li><li><a class="nounderline abstract_t">Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831.</a></li><li><a class="nounderline abstract_t">Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423.</a></li><li><a class="nounderline abstract_t">Markt SC, Rodriguez AC, Burk RD, et al. Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting. J Infect Dis 2012; 205:498.</a></li><li><a class="nounderline abstract_t">Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808.</a></li><li><a class="nounderline abstract_t">Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 2006; 110:525.</a></li><li><a class="nounderline abstract_t">Einstein MH, Burk RD. Persistent Human Papillomavirus Infection: definitions and clinical implications. Papillomavirus Report 2001; 12:119.</a></li><li><a class="nounderline abstract_t">Elfgren K, Elfström KM, Naucler P, et al. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol 2017; 216:264.e1.</a></li><li><a class="nounderline abstract_t">Tambouret R, Pitman MB, Bell DA. Benign glandular cells in posthysterectomy vaginal smears. Acta Cytol 1998; 42:1403.</a></li><li><a class="nounderline abstract_t">Khan MJ, Massad LS, Kinney W, et al. A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 2016; 141:364.</a></li></ol></div><div id="topicVersionRevision">Topic 3205 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1548812" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : From the National Institutes of Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11966386" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The 2001 Bethesda System: terminology for reporting results of cervical cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931431" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Pap test and Bethesda 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25943863" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18369299" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cervical cytology specimen adequacy: patient management guidelines and optimizing specimen collection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19061816" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Overview of the cytology laboratory: specimen processing through diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17826171" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Human papillomavirus and cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22689991" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12052599" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Liquid-based Papanicolaou smears without a transformation zone component: should clinicians worry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18484643" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3859130" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3459326" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Papanicolaou smears without endocervical cells. Are they inadequate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10577637" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Efficacy of cervical-smear collection devices: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11507695" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Longitudinal analysis of histologic high-grade disease after negative cervical cytology according to endocervical status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1671112" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Longitudinal study of women with negative cervical smears according to endocervical status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11392881" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Endocervical status is not predictive of the incidence of cervical cancer in the years after negative smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550967" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Loss to follow-up of cervical smears without endocervical columnar cells is not disturbing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28102052" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926787" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15471249" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cervical cytology screening history of women diagnosed with adenocarcinoma in situ of the cervix: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665217" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12412168" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19961244" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Unsatisfactory reporting rates: 2006 practices of participants in the college of american pathologists interlaboratory comparison program in gynecologic cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508662" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12890808" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Outcome of women with inadequate cervical smears followed up for five years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196011" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinicopathologic correlation of the unsatisfactory Papanicolaou smear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15981813" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical significance of unsatisfactory conventional pap smears owing to inadequate squamous cellularity defined by the Bethesda 2001 criterion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23519301" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210924" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The significance of benign endometrial cells in cervicovaginal smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106259" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Normal endometrial cells in cervical cytology: systematic review of prevalence and relation to significant endometrial pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3604537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The presence of endometrial cells in cervical smears in relation to the day of the menstrual cycle and the method of contraception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14058042" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : NORMAL EXFOLIATION OF ENDOMETRIAL CELLS IN PREMENOPAUSAL WOMEN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17604086" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Bethesda System 2001 recommendation for reporting of benign appearing endometrial cells in Pap tests of women age 40 years and older leads to unwarranted surveillance when followed without clinical qualifiers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16329117" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence and clinical significance of morphologically benign-appearing endometrial cells in patients age 40 years or older: the impact of the 2001 Bethesda System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16633242" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Endometrial cells in cervical cytology: review of cytological features and clinical assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15900572" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Significance of benign endometrial cells in papanicolaou tests from women aged&gt;or=40 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743742" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Reporting endometrial cells in women 40 years and older: assessing the clinical usefulness of Bethesda 2001.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11599107" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical relevance of benign endometrial cells in postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136567" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cytologically benign endometrial cells in the papanicolaou smears of postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17547898" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Endometrial cells identified in cervical cytology in women&gt;or = 40 years of age: criteria for appropriate endometrial evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22102567" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : In Papanicolaou smears, benign appearing endometrial cells bear no significance in predicting uterine endometrial adenocarcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592239" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accuracy of detection of trichomonas vaginalis organisms on a liquid-based papanicolaou smear.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11014723" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A meta-analysis of the Papanicolaou smear and wet mount for the diagnosis of vaginal trichomoniasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819823" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The papanicolaou smear: inadequate screening test for bacterial vaginosis during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8513711" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Value of Papanicolaou smear in detection of Chlamydia trachomatis infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12388995" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The significance of hyperkeratosis/parakeratosis on otherwise normal Papanicolaou smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2170888" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Colposcopic survey of Papanicolaou test-negative cases with hyperkeratosis or parakeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243307" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19407678" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410098" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11410191" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9459645" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Natural history of cervicovaginal papillomavirus infection in young women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22147792" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Longitudinal analysis of carcinogenic human papillomavirus infection and associated cytologic abnormalities in the Guanacaste natural history study: looking ahead to cotesting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871112" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16597322" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Molecular biology of human papillomavirus infection and cervical cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Persistent Human Papillomavirus Infection: definitions and clinical implications</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27825977" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850650" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Benign glandular cells in posthysterectomy vaginal smears.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915529" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
